Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

292 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Baseline Characteristics of a National French E-Cohort of Hidradenitis Suppurativa in ComPaRe and Comparison with Other Large Hidradenitis Suppurativa Cohorts.
Condamina M, Penso L, Tran VT, Hotz C, Guillem P, Villani AP, Perrot P, Bru MF, Jacquet E, Nassif A, Bachelez H, Wolkenstein P, Beylot-Barry M, Richard MA, Ravaud P, Viguier M, Sbidian E. Condamina M, et al. Among authors: bachelez h. Dermatology. 2021;237(5):748-758. doi: 10.1159/000513447. Epub 2021 Jan 27. Dermatology. 2021. PMID: 33503635 Free article.
First-Line Biologic Therapy and Obesity in Moderate-to-Severe Psoriasis: Results from the Prospective Multicenter Cohort Psobioteq.
Assan F, Tubach F, Arlegui H, Viguier M, Beylot-Barry M, Dupuy A, Beneton N, Joly P, Jullien D, Mahé E, Paul C, Richard MA, Bachelez H, Giboin C, Chosidow O, Sbidian E; and Psobioteq. Assan F, et al. Among authors: bachelez h. Dermatology. 2021;237(3):338-346. doi: 10.1159/000513398. Epub 2021 Feb 3. Dermatology. 2021. PMID: 33535213
A Multicentre Randomised Controlled Study Evaluating the Effect of a Standardised Education Programme on Quality of Life, Disease Severity, and Disease Knowledge in Patients with Moderate-To-Severe Psoriasis: The EDUPSO Study.
Jendoubi F, Balica S, Richard MA, Chiaverini C, Bernier C, Quiles N, Bachelez H, Beylot-Barry M, Mallet S, Goujon C, Parier J, Misery L, Carrere F, Lauwers-Cances V, Paul C; French Psoriasis Research Group. Jendoubi F, et al. Among authors: bachelez h. Dermatology. 2022;238(4):630-639. doi: 10.1159/000520289. Epub 2021 Dec 9. Dermatology. 2022. PMID: 34883480 Clinical Trial.
Terbinafine-induced subacute cutaneous lupus erythematosus.
Farhi D, Viguier M, Cosnes A, Reygagne P, Dubertret L, Revuz J, Roujeau JC, Bachelez H. Farhi D, et al. Among authors: bachelez h. Dermatology. 2006;212(1):59-65. doi: 10.1159/000089024. Dermatology. 2006. PMID: 16319476
Successive sebopsoriasis, erysipelas and Koebner phenomenon.
Viguier M, Bachelez H. Viguier M, et al. Among authors: bachelez h. CMAJ. 2010 Apr 6;182(6):E252. doi: 10.1503/cmaj.091387. Epub 2010 Mar 8. CMAJ. 2010. PMID: 20212027 Free PMC article. No abstract available.
Evolution of Drug Survival with Biological Agents and Apremilast Between 2012 and 2018 in Patients with Psoriasis from the PsoBioTeq Cohort.
Bettuzzi T, Bachelez H, Beylot-Barry M, Arlégui H, Paul C, Viguier M, Mahé E, Beneton N, Jullien D, Richard MA, Joly P, Tubach F, Dupuy A, Sbidian E, Chosidow O; PsoBioTeq study group. Bettuzzi T, et al. Among authors: bachelez h. Acta Derm Venereol. 2022 Mar 8;102:adv00665. doi: 10.2340/actadv.v101.566. Acta Derm Venereol. 2022. PMID: 34806759 Free PMC article.
Use of Complementary and Alternative Medicines by Patients with Psoriasis: Results from a Study with 2562 Patients.
Misery L, Shourick J, Sénéschal J, Paul C, de Pouvourville G, Jullien D, Mahé E, Bachelez H, Aubert R, Joly P, Héas S, Reguiai Z, Ezzedine K, Taieb C, Richard MA. Misery L, et al. Among authors: bachelez h. Am J Clin Dermatol. 2021 Mar;22(2):285-287. doi: 10.1007/s40257-021-00587-7. Epub 2021 Feb 21. Am J Clin Dermatol. 2021. PMID: 33611727 No abstract available.
292 results